Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2002
12/17/2002US6495555 Tricyclic Δ-3-piperidines as α2-antagonists
12/17/2002US6495554 Phosphodiesterase v inhibitors, treating cardiovascular disorders, and therapy of erectile dysfunction.
12/17/2002US6495553 Methods and compositions for overcoming resistance to biologic and chemotherapy
12/17/2002US6495552 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid.
12/17/2002US6495549 1-heteroaryl-piperidine derivatives; moderating neuronal degeneration; promoting neuronal regeneration and outgrowth; treatog neurological disorders arising from neurodegenerative diseases or other disorders involving nerve damage
12/17/2002US6495547 Hampered or impaired relaxation of the fundus to food ingestion; irritable bowel syndrome, anorexia, bloating, early satiety, dyspepsia
12/17/2002US6495546 Propanolamine derivatives
12/17/2002US6495544 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase
12/17/2002US6495543 Treating or preventing melatoninergic disorders
12/17/2002US6495542 Such as 2-methoxy-n-(2-methyl-1h-benzimidazol-4-yl)-4-(2,3,4,5-tetrahydro-5-oxo-1h-1-benzazepin-1-yl)carbonyl-benzam ide; hypertension, heart failure, renal insufficiency, edema, ascites, vasopressin parasecretion syndrome
12/17/2002US6495541 Tricyclic inhibitors of poly(ADP-ribose) polymerases
12/17/2002US6495534 Stabilized aqueous suspensions for parenteral use
12/17/2002US6495533 Drugs containing phosphoric acid derivatives as the active ingredient
12/17/2002US6495528 Antiinflammatory agents; inhibiting leukocyte recruitment and activation; agonists of adenosine 2a receptor
12/17/2002US6495526 Inhibitors of cell-cycle progression and uses related thereto
12/17/2002US6495525 N-((4-(((2-methylphenylamino)carbonyl)amino)phenyl)acetyl)-l -prolyl-3-methyl)-beta-alanine; very late antigen-4 cell adhesion inhibitor; inflammation and immune reactions
12/17/2002US6495522 Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
12/17/2002US6495519 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
12/17/2002US6495517 Cyclooxygenase inhibitor
12/17/2002US6495516 Method for killing gram-negative bacteria with biologically active peptides from functional domains of bacterial/permeability-increasing protein
12/17/2002US6495359 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
12/17/2002US6495347 Determining if fusion protein stimulates a th1-like response in cell sample; fusion proteins and conjugates that contain at least a portion of a heat shock protein; response detected by measuring interferon (ifn)-gamma produced by the cell sample
12/17/2002US6495346 Do not react with foreign partners; amino acids inserted into proteins which naturally form dimers, mutated proteins only form complexes with themselves (homodimers) or with the mutated partner (heterodimers), not with nonmutated starting
12/17/2002US6495332 Methods and compositions for ameliorating the symptoms of sepsis
12/17/2002US6495165 Eplerenone compositions having improved bioavailability
12/17/2002US6495154 On demand administration of clomipramine and salts thereof to treat premature ejaculation
12/17/2002US6495135 Immortalized human keratinocyte cell line
12/17/2002CA2260311C Remedy for cag repeat expansion diseases
12/17/2002CA2246560C Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy
12/17/2002CA2214439C A novel growth factor and a genetic sequence encoding same
12/17/2002CA2203389C Bicyclic heterocyclic compounds for the treatment of impotence
12/17/2002CA2188688C Use of lanthanide, tin, zinc, manganese, yttrium, cobalt, barium, strontium salt in a skin care composition
12/17/2002CA2148652C Substance p antagonist used in a cosmetic composition; composition thus produced
12/17/2002CA2131822C Use of estriol for treating climacteric osteoporosis
12/17/2002CA2085464C Using 5,10,15,10-tetrakis (r-carboxyphenyl)porphine for detecting and treating lung cancer
12/17/2002CA2064783C Cytoprotective fatty moiety compounds
12/14/2002CA2390686A1 Cofactor-based screening method for nuclear receptor modulators and related modulators
12/12/2002WO2002099427A1 Srpks as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099426A1 Pecis as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099140A1 GLRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099138A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099125A1 PIBs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099122A1 Modifiers of the p53 pathway and methods of use
12/12/2002WO2002099110A1 Cell cycle regulatory factor
12/12/2002WO2002099102A1 Numb protein expression inhibitors by musashi
12/12/2002WO2002099083A2 Gfats as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099075A2 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099074A2 Slc7s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099060A2 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099059A2 U5-200KDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099058A2 KCNMAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099057A2 Sams modifiers of the p53 pathway and methods of use
12/12/2002WO2002099056A2 C22c7orfs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099055A2 Cips as modifiers of the p53 pathway and method of use
12/12/2002WO2002099054A2 Hccss as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099053A2 Slc22as as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099052A2 Opns as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099051A2 Nits as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099050A2 Tprs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099049A2 Tbc1d1s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099048A2 LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099047A2 PROMLs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099046A2 Spo11 as modifier of the p53 pathway and methods of use
12/12/2002WO2002099044A2 B3galts as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099042A2 Cads as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099041A2 Ces2s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099040A2 Igs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099038A2 Adsls as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099037A2 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
12/12/2002WO2002098907A2 Cation conducting gabaa receptors and their use
12/12/2002WO2002098899A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098898A2 FLJs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098893A1 Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
12/12/2002WO2002098890A2 MARKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098885A1 Modified psma ligands and uses related thereto
12/12/2002WO2002098880A1 5-ethyl-imidazotriazinones
12/12/2002WO2002098878A1 Trifluoromethylpurines as phosphodiesterase 4 inhibitors
12/12/2002WO2002098877A1 Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
12/12/2002WO2002098876A1 Cak inhibitors and uses thereof
12/12/2002WO2002098875A1 Carboline derivatives as pde-5 inhibitors
12/12/2002WO2002098873A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002WO2002098872A1 Isoindolines and process for preparation thereof
12/12/2002WO2002098871A1 Phenylcarboxamides and process for preparation thereof
12/12/2002WO2002098869A2 1,4-disubstituted benzo-fused cycloalkyl urea compounds
12/12/2002WO2002098865A2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
12/12/2002WO2002098864A1 Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
12/12/2002WO2002098860A1 Novel fused indazoles and indoles and their use for the treatment of glaucoma
12/12/2002WO2002098857A1 New indole derivatives with 5-ht6 receptor affinity
12/12/2002WO2002098856A2 Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists
12/12/2002WO2002098854A2 Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
12/12/2002WO2002098852A2 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
12/12/2002WO2002098850A2 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
12/12/2002WO2002098849A2 Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
12/12/2002WO2002098847A1 Cycloalkenylsulfonamide derivatives
12/12/2002WO2002098846A1 Sulfonamide derivatives
12/12/2002WO2002098840A1 Carboxylic acid derivative and medicine comprising salt or ester of the same
12/12/2002WO2002098839A1 Biphenylcarboxamides and process for preparation thereof
12/12/2002WO2002098511A1 Compositions comprising oestrone-3-0-sulphamate and trail (tnf-related apoptosis inducing ligand)
12/12/2002WO2002098467A1 Slc2as as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098463A1 Antifungal compositions
1 ... 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 ... 1564